fashion -WSS

fashion

author：explore 2025-09-10 05:02:38 - browse：42

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Study: AI not yet building 'n

focus

WSS

H5N1 bird flu: what we're starting to learn about infection in cows

H5N1 bird flu: what we're starting to learn about infection in cows

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Americans' trust in science, scientist continues decline: Report

H5N1 communication has been strictly for the birds

First recipient of genetically engineered pig kidney has died

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Affirmative action in medical school literally saved lives

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Medicare details structure of new drug price negotiation program

Apple Watch's A

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

What PEPFAR has meant on the ground in Ukraine

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

H5N1 communication has been strictly for the birds

hotspot

Pregnancy discrimination could be enabled by AI

After gene therapy, two congenitally deaf children hear for the first time

Pfizer plans to depart BIO

Leukemia patients are helped by Syndax's new type of therapy

Americans' trust in science, scientist continues decline: Report

Radiology is caught between AI's potential and concern for patients

entertainment

focus

focus

focus